CANX

Calnexin · P27824 · CANX on Sugi Atlas →

0 patent compounds predicted against CANX, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CANX by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Reducing the Risk of Drug-Induced QT Interval Lengthening in Women PHASE4COMPLETED
Cardioprotective Empagliflozin for Cancer Patients Receiving Doxorubicin PHASE2/PHASE3UNKNOWN
Early Study on Tamoxifen Safety/Tolerability in Cystic Fibrosis Patients Unable to Use CFTR Modulators. PHASE2NOT_YET_RECRUITING
A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1 PHASE1/PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma PHASE2RECRUITING
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
A Study of CAN008 for Newly Diagnosed Glioblastoma Multiforme PHASE1COMPLETED
Dose-Escalation Phase 1 Study of G-202 (Mipsagargin) in Patients With Advanced Solid Tumors PHASE1COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer PHASE1COMPLETED
Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D) EARLY_PHASE1COMPLETED
Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study nanRECRUITING
Predicting Pancreatic Necrosis Using mitDNA nanUNKNOWN
Detection of Circulating Biomarkers of Immunogenic Cell Death nanCOMPLETED
Carnosine Supplementation on Quantity/Quality of Oral Salivae. nanUNKNOWN
Dynamics of Muscle Mitochondria in Type 2 Diabetes Exercise nanCOMPLETED
MERC Proteins in Saliva and GCF in Periodontal Disease (ELISA Study) nanCOMPLETED
Observational Study of Blood Treated With Cytolin nanCOMPLETED
The Etiology and Progression of Brain Tumors nanCOMPLETED
IMI PROTECT (Work Package 2): Calcium Channel Blockers and Cancer nanCOMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients nanUNKNOWN
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions nanCOMPLETED
To Detect Cryoimmunologic Response Induced by Early Breast Cancer Ultrasound-guided Cryoablation (ICE-study) nanCOMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients nanUNKNOWN
S100A8 in Serum and Urine as a New Biomarker in Lupus Nephritis nanCOMPLETED
Preliminary Study for Identification of Calcium-Binding Proteins in the Serum in Various Metabolic Bone Disorders nanUNKNOWN
The Energetic Origin of Neurodegeneration in MS nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CANX binder may also engage these)

ProteinNameSimilarity
P35564 1.000 P35564 →
P52194 1.000 P52194 →
Q5R440 1.000 Q5R440 →
O14967 1.000 O14967 →
P24643 1.000 P24643 →
P35565 1.000 P35565 →
Q39994 0.999 Q39994 →
Q39817 0.997 Q39817 →
A8XA40 0.997 A8XA40 →
Q9XF98 0.996 Q9XF98 →
Q9SLY8 0.995 Q9SLY8 →
O04153 0.995 O04153 →
Q38858 0.995 Q38858 →
Q23858 0.994 Q23858 →
Q06814 0.993 Q06814 →
E2RA18 0.993 E2RA18 →
Q4VIT5 0.992 Q4VIT5 →
Q4R6K8 0.992 Q4R6K8 →
Q38798 0.992 Q38798 →
Q9D9Q6 0.992 Q9D9Q6 →
O81919 0.992 O81919 →
P93508 0.992 P93508 →
CALR Calreticulin 0.991 landscape →
A0A0D1C6P2 0.991 A0A0D1C6P2 →
Q61KR9 0.991 Q61KR9 →
J9VLH0 0.991 J9VLH0 →
Q8K3H7 0.991 Q8K3H7 →
Q9ZPP1 0.991 Q9ZPP1 →
P34652 0.991 P34652 →
P29402 0.991 P29402 →